Serina Therapeutics Inc (SER) Stock Price, Quote & News

Company Profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which...

Industry: Biotechnology

Sector: Healthcare

Phone: 256 327 9630

Website: serinatherapeutics.com

Address:

601 Genome Way, Suite 2001, Huntsville, United States

BryanGreenwater Feb. 23 at 1:16 PM

$SER double from here, then lower than it started. rinse and repeat, if you time it right, you can score big.

0 · Reply

Monogg Feb. 21 at 1:07 AM

$SER Traded this shit, these are scammers, Juvicence are business parasites, they steal investors’ money, second RS coming soon, stay away, all your money will go to pay for their houses and cars. Nothing personal, just business and observations.

0 · Reply

BryanGreenwater Feb. 19 at 3:10 PM

$SER need some volume for a spike

0 · Reply

Golferhack12 Feb. 18 at 5:44 PM

$SER this company has nothing completely dead when you're at this stage your PR team needs to be a machine and put stuff out there not just some b******* press release every month the stock gaps up and then it goes right back down and further down until the next one

0 · Reply

Golferhack12 Feb. 17 at 9:01 PM

$SER it's very hard to hold on to this thing has had an all-time low and there's no volume whatsoever it looks like it wants to go much lower very hard to hold on to it big disappointment

1 · Reply

PortfolioEssence Feb. 17 at 1:24 PM

$SER Micro-cap biotech; early-stage.

0 · Reply

cb5000calls Feb. 16 at 2:22 PM

$SLS @Love_To_Learn we all know she's ready... are you ready? What more do you need from longs before you are ready to let her launch? Tracks laid for SLS launch by: $AQST $GCTK $SER $ACRS

1 · Reply

DanSap4320 Feb. 13 at 4:03 PM

$SER What happen? Any news related to that upside today?

1 · Reply

BryanGreenwater Feb. 13 at 3:30 PM

$SER looks like bottom is in

0 · Reply

BryanGreenwater Feb. 12 at 8:15 PM

$SER Low volume...

0 · Reply

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Feb 19, 2026, 6:00 AM EST - 7 days ago

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Feb 3, 2026, 6:00 AM EST - 23 days ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event

Jan 28, 2026, 4:12 PM EST - 4 weeks ago

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease

Jan 15, 2026, 4:30 PM EST - 5 weeks ago

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

Dec 11, 2025, 4:15 PM EST - 2 months ago

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Dec 10, 2025, 4:30 PM EST - 2 months ago

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Nov 13, 2025, 6:10 AM EST - 3 months ago

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 3, 2025, 6:05 AM EST - 4 months ago

Serina Therapeutics Provides Regulatory Update on SER-252 Program

Oct 8, 2025, 11:00 AM EDT - 5 months ago

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Oct 6, 2025, 4:15 PM EDT - 5 months ago

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

Sep 9, 2025, 3:20 PM EDT - 6 months ago

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Sep 8, 2025, 6:00 AM EDT - 6 months ago

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 4:15 PM EDT - 6 months ago

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Aug 11, 2025, 4:30 PM EDT - 7 months ago

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Jul 29, 2025, 6:44 AM EDT - 7 months ago

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Jul 28, 2025, 6:00 AM EDT - 7 months ago

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Jul 10, 2025, 4:10 PM EDT - 8 months ago

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 1, 2025, 4:15 PM EDT - 8 months ago

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Jun 23, 2025, 7:24 PM EDT - 8 months ago

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

Jun 17, 2025, 8:30 PM EDT - 9 months ago

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 6:00 AM EDT - 9 months ago

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Jun 9, 2025, 4:05 PM EDT - 9 months ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

May 22, 2025, 4:50 PM EDT - 9 months ago

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 14, 2025, 3:15 PM EDT - 10 months ago

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 8, 2025, 4:23 PM EDT - 10 months ago

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Apr 29, 2025, 6:00 AM EDT - 10 months ago

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Apr 15, 2025, 6:30 AM EDT - 11 months ago

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Apr 8, 2025, 4:30 PM EDT - 11 months ago

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Apr 7, 2025, 6:30 AM EDT - 11 months ago

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:30 PM EDT - 1 year ago

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Feb 12, 2025, 4:15 PM EST - 1 year ago

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Feb 3, 2025, 4:30 PM EST - 1 year ago

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Jan 15, 2025, 4:05 PM EST - 1 year ago

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Jan 14, 2025, 5:25 PM EST - 1 year ago

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Dec 16, 2024, 6:00 AM EST - 1 year ago

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Dec 11, 2024, 6:05 AM EST - 1 year ago

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Dec 2, 2024, 5:22 PM EST - 1 year ago

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Nov 12, 2024, 5:00 PM EST - 1 year ago

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Sep 4, 2024, 6:42 PM EDT - 1 year ago

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 4:15 PM EDT - 1 year ago

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Jul 18, 2024, 5:00 PM EDT - 1 year ago

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

May 14, 2024, 4:05 PM EDT - 1 year ago

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 17, 2024, 4:05 PM EDT - 2 years ago

Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman

Mar 26, 2024, 5:04 PM EDT - 2 years ago

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

Mar 22, 2024, 5:27 PM EDT - 2 years ago

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

Feb 27, 2024, 3:19 PM EST - 2 years ago

AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE

Nov 14, 2023, 4:05 PM EST - 2 years ago

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

BryanGreenwater Feb. 23 at 1:16 PM

$SER double from here, then lower than it started. rinse and repeat, if you time it right, you can score big.

0 · Reply

Monogg Feb. 21 at 1:07 AM

0 · Reply

BryanGreenwater Feb. 19 at 3:10 PM

$SER need some volume for a spike

0 · Reply

Golferhack12 Feb. 18 at 5:44 PM

0 · Reply

Golferhack12 Feb. 17 at 9:01 PM

$SER it's very hard to hold on to this thing has had an all-time low and there's no volume whatsoever it looks like it wants to go much lower very hard to hold on to it big disappointment

1 · Reply

PortfolioEssence Feb. 17 at 1:24 PM

$SER Micro-cap biotech; early-stage.

0 · Reply

cb5000calls Feb. 16 at 2:22 PM

$SLS @Love_To_Learn we all know she's ready... are you ready? What more do you need from longs before you are ready to let her launch? Tracks laid for SLS launch by: $AQST $GCTK $SER $ACRS

1 · Reply

DanSap4320 Feb. 13 at 4:03 PM

$SER What happen? Any news related to that upside today?

1 · Reply

BryanGreenwater Feb. 13 at 3:30 PM

$SER looks like bottom is in

0 · Reply

BryanGreenwater Feb. 12 at 8:15 PM

$SER Low volume...

0 · Reply

BryanGreenwater Feb. 12 at 10:24 AM

$SER All in, looking for a double from current levels

0 · Reply

Golferhack12 Feb. 12 at 2:13 AM

$SER new all time low today broke support good buying opportunity I'm

0 · Reply

dthekang Feb. 12 at 12:54 AM

$SER F sake

0 · Reply

BryanGreenwater Feb. 11 at 2:40 PM

$SER lets go, slow and steady

1 · Reply

BryanGreenwater Feb. 6 at 5:45 PM

$SER Added. low volume drop

0 · Reply

BuyTheDip45 Feb. 6 at 1:55 PM

$SER bought

0 · Reply

Bullbear1010101 Feb. 4 at 5:30 PM

$SER dumped like 99 percent of the high flier pumps

0 · Reply

jheerdink Feb. 4 at 4:48 PM

$SER We are live now with Serina's CEO a large group of Tribe members. Please join us. Register here http://New-FDA-Era.TribePublic.com

0 · Reply

Rampageusa Feb. 4 at 3:16 PM

$BOXL ,$XHLD,$SER pending runs above 5++

0 · Reply

PaulThomasTPG Feb. 4 at 2:20 PM

$SER Get ready for the opening bell 🧑‍🚀$LLY $MRNA https://youtu.be/-I-dRDxCD00

0 · Reply

PaulThomasTPG Feb. 4 at 2:13 PM

$SER $BBAI UP 11% premarket, and just getting started

1 · Reply

jheerdink Feb. 3 at 2:05 PM

$SER register for Feb.4 Tribe Public Serina Therapeutics Webinare Event at 11:30am et at http://New-FDA-Era.TribePublic.com

0 · Reply

Market Cap	18.01M
Revenue (ttm)	60,000.00
Net Income (ttm)	-11.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18,566.67%
Debt to Equity Ratio	0.00

Volume	89,000
Avg Vol	1,643,340
Day's Range	N/A - N/A
Shares Out	10.79M
Stochastic %K	50%
Beta	1.20
Analysts	Strong Sell
Price Target	$13.00